WINDLAS Windlas Biotech Q1 FY26 results (Apr–Jun 2025) and concall
Windlas Biotech delivered a strong Q1 FY26 performance, achieving its tenth consecutive quarter of record revenue. The company reported robust growth across all business verticals, coupled with significant margin expansion. Strategic initiatives, including the refurbishment of Plant 6 and expansion of the injectable facility, are on track to enhance future capacity and drive long-term value.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY26: revenue up 20.0%, net profit up 38.5% against the same quarter last year.
| Line item | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|---|
| Revenue | 175 | 187 | 195 | 203 | 210 +20% |
| EBITDA | 21 | 23 | 25 | 26 | 27 +29% |
| Net profit | 13 | 16 | 16 | 16 | 18 +38% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
